| Drug Name: | Alprenolol (13655-52-2) |
|---|---|
| PubChem ID: | 2119 |
| SMILES: | CC(C)NCC(COC1=CC=CC=C1CC=C)O |
| InchiKey: | PAZJSJFMUHDSTF-UHFFFAOYSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Sympatholytics |
| Molecular Weight (dalton) | : | 249.354 |
| LogP | : | 2.1528 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 41.49 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Prazosin (19216-56-9) | Hypotension | Synergistic | Synergistic effect of prazosin along with Alprenolol | Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Increased Beta-Blockade | CYP2D6 (P10635) | Increased beta-blockade [ ADR Type 1 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category